Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy

Snegha Ananth, Jayasindhu Mallampet, Betty Chang, Neha Agarwal, Katherine Kong, Bita Sahaf, Juan Carlos Suarez Serrato, Ilan Kirsch, Allison Jacob, Heidi Simmons, Lik Wee Lee, Crystal Mackall, Wen-Kai Weng, Sushma Bharadwaj, Melody Smith, Saurabh Dahiya, David Miklos, Matthew Frank

Blood (2025) 146 (Supplement 1): 941.

https://doi.org/10.1182/blood-2025-941

Published: 2025

Journal Articles

Pre-CAR next generation sequencing informs patient outcomes in children and young adults with B-acute lymphoblastic leukemia

Rohaum Hamidi, Amy Zhang, Malka Handwerker, Dhruv Bhatt, Kara Davis, Sneha Ramakrishna, Catherine Aftandilian, Jennifer Moon, Ashley Jacobs, Emily DeYager, Courtney Erickson, Divya Madhav, Regina Dagher, Crystal Mackall, Tanja Gruber, Christina Baggott, Lik Wee Lee, Ilan Kirsch, Liora Schultz

Blood (2025) 146 (Supplement 1): 550.

https://doi.org/10.1182/blood-2025-550

Published: 2025

Journal Articles

Blinatumomab mitigates the impact of traditional adverse prognosticators among children with standard risk b-acute lymphoblastic leukemia: Updated results of the Children's oncology group (COG) Trial AALL1731

Blood (2025) 146 (Supplement 1): 758.

https://doi.org/10.1182/blood-2025-758

Published: 2025

Journal Articles

Evaluating flow cytometry (FC) and next generation sequencing (NGS) for assessing minimal residual disease (MRD) and B-cell aplasia (BCA) in children, adolescents and young adults (CAYA) with B-cell acute lymphoblastic leukemia (B-ALL)

Chelsea O'Koren, Julie Ma, Bonnie Yates, Hao-Wei Wang, Constance Yuan, Chloe Hoang, Tanvi Verma, David Peske, Ilan Kirsch, Challice Bonifant, Nirali Shah

Blood (2025) 146 (Supplement 1): 3363.

https://doi.org/10.1182/blood-2025-3363

Published: 2025

Journal Articles

Immunoglobulin variable gene diversity reflects distinct metabolic/signaling states and impacts measurable residual disease monitoring and clinical outcome in B cell acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 333.

https://doi.org/10.1182/blood-2025-333

Published: 2025

Journal Articles

Comparison of paired bone marrow and peripheral blood measurable residual disease in pediatric acute lymphoblastic leukemia by next-generation sequencing: A report from the dana farber ALL consortium protocol 16-001.

Jennifer Welch, Yael Flamand, Victoria Koch, Peter Cole, Lisa Gennarini, Justine Kahn, Kara Kelly, Bruno Michon, Thai Hoa Tran, Ilan Kirsch, Heidi Simmons, Melissa Burns, Lewis Silverman, Marian Harris

Blood (2025) 146 (Supplement 1): 5146.

https://doi.org/10.1182/blood-2025-5146

Published: 2025

Journal Articles

T-cell clones of uncertain significance are prevalent in cutaneous T-cell lymphomas

Safa Najidh, Joseph Cleveland, Ryan Burke, Armando Bastidas Torres, Alexa Kwang, George Duran, Yonatan Cooper, Ilan Kirsch, Bing Zhang, Youn-H Kim, Michael Khodadoust

Blood (2025) 146 (Supplement 1): 5431.

https://doi.org/10.1182/blood-2025-5431

Published: 2025

Journal Articles

Tumor-Infiltrating Normal B Lymphocytes Have Remarkable Prognostic Effects and Are Crucial for Antitumor Immune Responses in Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 429.

https://doi.org/10.1182/blood-2023-179972

Published: 2023

Journal Articles

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Blood (2021) 137 (17): 2321–2325.

https://doi.org/10.1182/blood.2020009432

Published: 2021

Includes: Supplemental data

Journal Articles

Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL

Brent Wood, David Wu, Beryl Crossley, Yunfeng Dai, David Williamson, Charles Gawad, Michael J. Borowitz, Meenakshi Devidas, Kelly W. Maloney, Eric Larsen, Naomi Winick, Elizabeth Raetz, William L. Carroll, Stephen P. Hunger, Mignon L. Loh, Harlan Robins, Ilan Kirsch

Blood (2018) 131 (12): 1350–1359.

https://doi.org/10.1182/blood-2017-09-806521

Published: 2018

Includes: Supplemental data

Journal Articles

IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients

Michael A. Pulsipher, Chris Carlson, Bryan Langholz, Donna A. Wall, Kirk R. Schultz, Nancy Bunin, Ilan Kirsch, Julie M. Gastier-Foster, Michael Borowitz, Cindy Desmarais, David Williamson, Michael Kalos, Stephan A. Grupp

Blood (2015) 125 (22): 3501–3508.

https://doi.org/10.1182/blood-2014-12-615757

Published: 2015

Includes: Supplemental data

Journal Articles

High Throughput TCR Sequencing Provides Added Value in the Diagnosis of Cutaneous T-Cell Lymphoma

Ilan Kirsch, MD, David W Williamson, PhD, James Krueger, MD PhD, Jessica Teague, PhD, Christopher Elco, MD PhD, Harlan Robins, PhD, Thomas S. Kupper, MD, Rachael A Clark, MDPhD

Blood (2014) 124 (21): 1683.

https://doi.org/10.1182/blood.V124.21.1683.1683

Published: 2014

Journal Articles

Minimal Residual Disease Detection By Next Generation Sequencing in Adult B-Cell Acute Lymphoblastic Leukemia (ALL) Patients Treated on SWOG Trial S0333

Olga Sala Torra, MD, Megan Othus, PhD, David W Williamson, PhD, Brent L. Wood, MD PhD, Ilan Kirsch, MD, Harlan Robins, PhD, Margaret O'Donnell, Stephen J. Forman, Frederick R. Appelbaum, MD, Jerald P Radich, MD

Blood (2014) 124 (21): 2399.

https://doi.org/10.1182/blood.V124.21.2399.2399

Published: 2014

Journal Articles

Defining Immunoglobulin Somatic Hypermutation in De Novo Diffuse Large B-Cell Lymphoma Patients: Potential Application for Prognosis and Risk Stratification

Ilan Kirsch, MD, Zijun Yidan Xu-Monette, PhD, Thomas Snyder, PhD, Ken H. Young, MD PhD

Blood (2014) 124 (21): 1669.

https://doi.org/10.1182/blood.V124.21.1669.1669

Published: 2014

Journal Articles

Robust Detection Of Minimal Residual Disease In Unselected Patients With B-Cell Precursor Acute Lymphoblastic Leukemia By High-Throughput Sequencing Of IGH

David Wu, MD, PhD, Ryan O Emerson, PhD, Anna Sherwood, PhD, Mignon L. Loh, MD, Anne Angiolillo, MD, Ilan Kirsch, MD, Christopher S Carlson, PhD, David Williamson, PhD, Brent L. Wood, MD, PhD, Harlan Robins, PhD

Blood (2013) 122 (21): 2550.

https://doi.org/10.1182/blood.V122.21.2550.2550

Published: 2013

Journal Articles

On-Going Evolution Of IGH In B-Cell Precursor Acute Lymphoblastic Leukemia Does Not Substantially Affect Day 29, Post-Treatment MRD Quantification By High-Throughput Sequencing

Blood (2013) 122 (21): 1341.

https://doi.org/10.1182/blood.V122.21.1341.1341

Published: 2013

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy

Pre-CAR next generation sequencing informs patient outcomes in children and young adults with B-acute lymphoblastic leukemia

Blinatumomab mitigates the impact of traditional adverse prognosticators among children with standard risk b-acute lymphoblastic leukemia: Updated results of the Children's oncology group (COG) Trial AALL1731

Evaluating flow cytometry (FC) and next generation sequencing (NGS) for assessing minimal residual disease (MRD) and B-cell aplasia (BCA) in children, adolescents and young adults (CAYA) with B-cell acute lymphoblastic leukemia (B-ALL)

Immunoglobulin variable gene diversity reflects distinct metabolic/signaling states and impacts measurable residual disease monitoring and clinical outcome in B cell acute lymphoblastic leukemia

Comparison of paired bone marrow and peripheral blood measurable residual disease in pediatric acute lymphoblastic leukemia by next-generation sequencing: A report from the dana farber ALL consortium protocol 16-001.

T-cell clones of uncertain significance are prevalent in cutaneous T-cell lymphomas

Tumor-Infiltrating Normal B Lymphocytes Have Remarkable Prognostic Effects and Are Crucial for Antitumor Immune Responses in Diffuse Large B-Cell Lymphoma

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL

IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients

High Throughput TCR Sequencing Provides Added Value in the Diagnosis of Cutaneous T-Cell Lymphoma

Minimal Residual Disease Detection By Next Generation Sequencing in Adult B-Cell Acute Lymphoblastic Leukemia (ALL) Patients Treated on SWOG Trial S0333

Defining Immunoglobulin Somatic Hypermutation in De Novo Diffuse Large B-Cell Lymphoma Patients: Potential Application for Prognosis and Risk Stratification

Robust Detection Of Minimal Residual Disease In Unselected Patients With B-Cell Precursor Acute Lymphoblastic Leukemia By High-Throughput Sequencing Of IGH

On-Going Evolution Of IGH In B-Cell Precursor Acute Lymphoblastic Leukemia Does Not Substantially Affect Day 29, Post-Treatment MRD Quantification By High-Throughput Sequencing

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only